AXIVA HEALTH SOLUTIONS, INC. v. INFUSION CENTER OF PENNSYLVANIA LLC

CourtDistrict Court, E.D. Pennsylvania
DecidedApril 6, 2022
Docket2:21-cv-05313
StatusUnknown

This text of AXIVA HEALTH SOLUTIONS, INC. v. INFUSION CENTER OF PENNSYLVANIA LLC (AXIVA HEALTH SOLUTIONS, INC. v. INFUSION CENTER OF PENNSYLVANIA LLC) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
AXIVA HEALTH SOLUTIONS, INC. v. INFUSION CENTER OF PENNSYLVANIA LLC, (E.D. Pa. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA AXIVA HEALTH SOLUTIONS, INC., : Plaintiff : CIVIL ACTION : v. : : INFUSION CENTER OF : PENNSYLVANIA, : No. 21-5313 Defendant : MEMORANDUM PRATTER, J. APRIL 6, 2022 Axiva and Infusion Center of Pennsylvania (iCPA) have resolved the substance of their dispute regarding iCPA’s plans to rebrand as “Avita” by entering a stipulated permanent injunction. Axiva now seeks attorneys’ fees and costs for the action. The Court will grant the motion in part, with the admonition that the reasoning of the ruling should infuse both parties with a dose of common sense that can and should resolve the entire dispute. BACKGROUND Axiva and iCPA provide infusion services to patients in Pennsylvania. Upon ascertaining that iCPA had begun rebranding itself as “Avita,”1 Axiva sent a cease-and-desist letter to iCPA on November 12, 2021. Counsel for iCPA responded on November 22, 2021, asserting that iCPA/Avita would not comply with the cease-and-desist demand for several reasons. iCPA did not consider Axiva as a competitor because Axiva promotes vitamin infusions and other med-spa like services, in contrast to iCPA/Avita providing medical infusion services for the chronically ill. Its rebranding began in May 2021 and was, in its own assessment, “painstakingly documented.” Doc. No. 15-2, at 6. And, as an additional cause for distinguishing itself, Axiva is registered in New Jersey, where Avita does not operate. 1 Both “Avita” and “Axiva” are pronounced with a long “ee” sound for the letter “i.” Compl. ¶¶ 10, 24. Two weeks after 1CPA/Avita responded to the cease-and-desist letter, on December 3, 2021, Axiva simultaneously filed a complaint and a motion for a temporary restraining order to stop the iCPA rebranding activity. Axiva asserted Lanham Act and common law claims for trademark infringement and unfair competition based on the following alleged infringement:

A ° axiva avita fA Baler Care Experience”

Specifically, Axiva asserted that iCPA “has poached not only the exact font and color palette of the AXIVA Stylized Mark—that is, medium plum letters surrounding a dark plum letter—it has even included a small blue droplet hovering over one of the interior letters, quite similar to the droplets hovering over an interior letter of the AXTVA Stylized Mark.” Jd. § 23. Axiva also sought a TRO and preliminary injunction to enjoin iCPA from infringing upon its service marks by “[a]dvertising, soliciting, marketing, or otherwise using in any way the AXIVA Intellectual Property and confusingly similar versions thereof, including but not limited to the marks AVITA and AVITA INFUSION CENTERS, in connection with the provision of medical and/or wellness infusion services.” Doc. No. 2-2, at 2. The Court held a conference on December 14, 2021 to discuss the TRO procedures. At this conference, counsel for iCPA represented that 1CPA had already rebranded to Avita and so the TRO motion was moot. The Court encouraged the parties to discuss a standstill agreement while the Court took the TRO filings under consideration. Axiva then “immediately” hired an investigator to drive to all of 1iCPA’s locations to investigate iCPA’s lawyer’s assertion that the rebranding had already taken place. Doc. No. 15-1,

at 7. The investigator found no use of the Avita name at any of iCPA’s six locations. On December 16, iCPA’s lawyer met with his client and then told opposing counsel for Axiva that he had been mistaken and the rebranding had actually not yet begun. Axiva complains of a loss of time and money spent investigating this issue. Axiva also argues that, although iCPA’s counsel represented

at the conference that iCPA did not offer at-home infusion treatments (in order to distinguish the markets for the two companies), iCPA’s website says it does do so. The parties settled the substance of the claim on December 16, 2021, which was two days after the TRO conference and 13 days after the initiation of litigation. They agreed to a stipulated permanent injunction, which this Court entered on January 12, 2022. Axiva then filed a motion for attorneys’ fees and costs. Axiva seeks a total of $28,409 in attorneys’ fees and costs for the time spent on the case in November and December 2021 (by one senior associate, Julie Latsko), the filing and service fees, and the private investigator fee. The Court held a hearing on the fees request, at which iCPA presented its objections to the motion and then filed an amended memorandum in opposition. Invoking the applicable statute,

iCPA objects that the case is not “exceptional” for purposes of allowing fees under the Lanham Act, and that the amount of time expended for which a fee award is sought was disproportionate to a 13-day case. Legal Standard Under the Lanham Act, courts have discretion to grant attorneys’ fees to the “prevailing party” only “in exceptional cases” of trademark infringement. 15 U.S.C. § 1117(a). The statute “does not define an ‘exceptional case.’ ” Securacomm Consulting, Inc. v. Securacom Inc., 224 F.3d 273, 279–80 (3d Cir. 2000). The Court of Appeals for the Third Circuit has held that “an ‘exceptional’ case is simply one that stands out from others with respect to the substantive strength of a party’s litigating position (considering both the governing law and the facts of the case) or the unreasonable manner in which the case was litigated.” Fair Wind Sailing, Inc. v. Dempster, 764 F.3d 303, 314 (3d Cir. 2014). A request for attorneys’ fees must be “reasonable.” 15 U.S.C. § 1117(a). “Although the

availability of alternate sanctioning tools may factor into the district court’s decision whether to award fees under [§ 1117(a)] in a particular case, it does not bar an award of fees under the Act.” Securacomm Consulting, Inc., 224 F.3d at 282. Analysis I. Attorneys’ Fees Axiva seeks $28,409 in attorneys’ fees for time spent by one of its lawyers, Ms. Latsko, in November and December 2021. A. Prevailing Party In order to obtain attorneys’ fees, Axiva must first count as a “prevailing party” under the Lanham Act. 15 U.S.C. § 1117(a). This means Axiva must have “been awarded some relief by the

court.” Buckhannon Bd. & Care Home, Inc. v. W. Va. Dep’t of Health and Hum. Res., 532 U.S. 598, 603 (2001) (emphasis added). In contrast to a private settlement, “settlement agreements enforced through a consent decree may serve as the basis for an award of attorney’s fees” because they are “a court-ordered change in the legal relationship between the plaintiff and the defendant.” Id. at 604 (internal quotation marks omitted). Here, the parties reached a Stipulated Permanent Injunction enforced by a court order. Axiva thus counts as a prevailing party because it has been awarded some relief by the Court, albeit because the Court signed off on an agreed upon stipulated injunction, regardless of whether iCPA admits liability (it does not). B. Exceptional Case Next, the Court must determine whether this is an “exceptional” case. 15 U.S.C. § 1117(a). iCPA insists that this case is not exceptional because it did not engage in culpable conduct. True, prior to 2014, that was at least nominally the test in this Circuit. But the Supreme Court, in Octane

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hensley v. Eckerhart
461 U.S. 424 (Supreme Court, 1983)
Eaves v. County Of Cape May
239 F.3d 527 (Third Circuit, 2001)
Chanel, Inc. v. Gordashevsky
558 F. Supp. 2d 532 (D. New Jersey, 2008)
Fair Wind Sailing Inc v. H. Dempster
764 F.3d 303 (Third Circuit, 2014)
Betty Pelc v. John Jerome Nowak
596 F. App'x 768 (Eleventh Circuit, 2015)
Securacomm Consulting, Inc. v. Securacom Inc.
224 F.3d 273 (Third Circuit, 2000)
Octane Fitness, LLC v. Icon Health
134 S. Ct. 1749 (Supreme Court, 2014)
Rode v. Dellarciprete
892 F.2d 1177 (Third Circuit, 1990)

Cite This Page — Counsel Stack

Bluebook (online)
AXIVA HEALTH SOLUTIONS, INC. v. INFUSION CENTER OF PENNSYLVANIA LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/axiva-health-solutions-inc-v-infusion-center-of-pennsylvania-llc-paed-2022.